Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CRDL
SellHot AirCardiol Therapeutics Inc. · Healthcare · Canada · $227M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Cardiol Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing innovative anti-inflammatory and anti-fibrotic therapies for cardiovascular diseases. The company is advancing its lead drug candidate, CardiolRx, a pharmaceutically produced cannabidiol formulation, through clinical trials for conditions like acute myocarditis, aiming to address significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 0.7M | — |
| EPS | -0.35 | -0.32 | -0.37 | -0.28 | — | -0.24 | -0.23 | -0.24 | — |
| Shares | 64.0M | 65.4M | 82.6M | 100.3M | +56.5% | 116.8M | — | — | — |
| Debt | 52.8K | 0.1M | 0.1M | 90.9K | 19.9% | 77.5K | — | — | — |
| Equity | 37.8M | 20.5M | 17.9M | 12.9M | -30.0% | — | — | — | — |
| Op CF | -19.7M | -18.2M | -18.1M | -17.3M | — | -17.4M | — | — | — |
| Inv CF | -54.1K | -46.6K | -15.4K | -17.7K | — | — | — | — | — |
| Fin CF | -39.0K | -40.1K | 13.6M | 11.3M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CRDL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CRDL | Cardiol Therapeutics Inc.(you) | $227M | 23 | Sell |
| ACB | Aurora Cannabis Inc. | $254M | 36 | Hold |
| WEED.TO | Canopy Growth Corporation | $461M | 25 | Sell |
| TLRY | Tilray Brands, Inc. | $631M | 13 | Strong Sell |
| TSND.TO | TerrAscend Corp. | $243M | 61 | Hold |
| MLCO.CN | The More Life Company Corp. | $26M | 22 | Sell |
| VM.V | Voyageur Pharmaceuticals Ltd. | $28M | 20 | Sell |
| LEEF.CN | Leef Brands Inc. | $58M | 41 | Hold |
| OGI | Organigram Global Inc. | $171M | 64 | Hold |
| LSL.V | LSL Pharma Group Inc. | $30M | 15 | Strong Sell |
Peer medians: ROE -31.6% · P/E 17.3x · Gross margin 46.2%